<SEC-DOCUMENT>0001789769-21-000029.txt : 20210513
<SEC-HEADER>0001789769-21-000029.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513164050
ACCESSION NUMBER:		0001789769-21-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Instil Bio, Inc.
		CENTRAL INDEX KEY:			0001789769
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				832072195
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40215
		FILM NUMBER:		21920271

	BUSINESS ADDRESS:	
		STREET 1:		3963 MAPLE AVENUE
		STREET 2:		SUITE 350
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		(972) 499-3350

	MAIL ADDRESS:	
		STREET 1:		3963 MAPLE AVENUE
		STREET 2:		SUITE 350
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>instilbio-8xkq1x21.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie34498013bd54735a375fdb28a4b96f8_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 8-K </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)&#58; May 13, 2021</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">Instil Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter) </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">001-40215</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">83-2072195</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or Other Jurisdiction</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of Incorporation)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Commission</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">File Number)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IRS Employer</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identification No.)</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3963 Maple Avenue, Suite 350</font></div><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dallas, Texas</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">75219</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(Address of Principal Executive Offices)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(Zip Code)</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(972) 499-3350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below)&#58; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.577%"><tr><td style="width:1.0%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:36.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Title of each class</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Symbol(s)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name of each exchange on which registered</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common Stock, $0.000001 par value</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TIL</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Nasdaq Stock Market LLC</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#9746; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; &#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2021, Instil Bio, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the quarter ended March 31, 2021 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"></td><td style="width:2.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Exhibits</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.309%"><tr><td style="width:1.0%"></td><td style="width:7.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Description</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a href="q1-21earningspressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">Press release, dated May 1</a><a href="q1-21earningspressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">3</a><a href="q1-21earningspressrelease.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">, 2021.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The cover page of this report has been formatted in Inline XBRL.</font></td></tr></table></div><div style="text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:39.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.729%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Instil Bio, Inc.</font></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dated&#58; May 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Sandeep Laumas, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sandeep Laumas, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer and Chief Business Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q1-21earningspressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i97407c532d404623955740fe7dd7a06b_1"></div><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image_01.jpg" src="image_01.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IPO in March 2021 raising $368M in gross proceeds</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DALLAS, TX, May 13, 2021 (GLOBE NEWSWIRE)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Instil Bio, Inc. (&#8220;Instil&#8221;) (NASDAQ&#58; TIL), a clinical-stage biopharmaceutical company developing tumor infiltrating lymphocytes, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2021 financial results and provided a corporate update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In March of 2021, Instil completed an initial public offering to support the development of our TIL therapies. We believe that our continued investment in cell manufacturing and process science will enable the development of our current and future product candidates, with a goal of providing broad patient access,&#8221; said Bronson Crouch, Chief Executive Officer of Instil. &#8220;We recently presented clinical data from our compassionate use program at the AACR conference and received orphan drug designation from the U.S. Food and Drug Administration for ITIL-168 in melanoma. We continue to advance ITIL-168 towards a potentially registration-enabling Phase 2 clinical trial in advanced melanoma, which we expect to initiate in the second half of this year.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2021 Highlights and Upcoming Anticipated Milestones</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.03pt">Completed Initial Public Offering&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> On March 23, 2021, Instil closed its initial public offering of 18,400,000 shares of common stock, including the full exercise of the underwriters&#8217; option to purchase an additional 2,400,000 shares of common stock at the public offering price of $20.00 per share. The gross proceeds of the offering were $368 million, before underwriting discounts and commissions and other offering expenses payable by Instil. The Company&#8217;s common stock now trades on the Nasdaq Global Select Market under the symbol &#8220;TIL.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical and Regulatory&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.03pt">Orphan Drug Designation for ITIL-168&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> On April 27, 2021 Instil received orphan drug designation from the U.S. Food and Drug Administration for the treatment of melanoma stages IIB to IV for its ITIL-168 TIL product candidate.</font></div><div style="text-indent:13.5pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.03pt">American Association for Cancer Research (AACR) Virtual Annual Meeting&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Presented late-breaking e-Poster on clinical data from a compassionate use program for the treatment of metastatic melanoma at the AACR virtual meeting April 10 &#8211; 15, 2021.</font></div><div style="text-indent:-4.5pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.03pt">Upcoming Phase 2 Clinical Trial&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Instil expects to initiate a Phase 2 clinical trial of ITIL-168 for the treatment of advanced melanoma and begin enrolling patients in the second half of 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image_01.jpg" src="image_01.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.03pt">Facility Readiness for Clinical Trials&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Manufacturing facilities in the United Kingdom are functional and ready to support clinical manufacturing for the upcoming ITIL-168 clinical trial, with additional capacity expected to come online later this year. Instil also expects U.S. clinical manufacturing to be online in the first half of 2022.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2021 Financial and Operating Results&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, cash and cash equivalents totaled $609.6 million, compared to $241.7 million as of December&#160;31, 2020. The Company expects that its cash and cash equivalents as of March&#160;31, 2021 will enable it to fund its operating plan into 2023. </font></div><div><font><br></font></div><div style="padding-left:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended March&#160;31, 2021 were $14.4 million, compared to $2.0 million for the same period in 2020.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended March&#160;31, 2021 were $9.0 million, compared to $1.9 million for the same period in 2020.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INSTIL BIO, INC.</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited&#59; in thousands, except share and per share amounts) </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Statements of Operations</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,424&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,007&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,979&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,900&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,403&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,907&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(23,403)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,863)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest and other income (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(226)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss before income tax expense</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(23,332)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,089)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Income tax benefit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">204&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(23,128)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,089)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</font></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.66)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.31)</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34,976,652&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,997,353&#160;</font></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image_01.jpg" src="image_01.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"></div></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selected Balance Sheet Data</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:65.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31, 2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">609,639&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">241,714&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">696,142&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">319,012&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,645&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity (deficit)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">665,153&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(39,599)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Instil Bio</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Instil Bio, Inc. (Nasdaq&#58; TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the company&#8217;s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.instilbio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and LinkedIn.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div style="margin-bottom:23pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; and &#8220;future&#8221; or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, whether, if approved, these product candidates will be successfully distributed and marketed, and the potential benefits of orphan drug designation to ITIL-168. Forward-looking statements are based on management&#8217;s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (&#8220;SEC&#8221;) filings,  including in our prospectus dated March 18, 2021, as filed with the  SEC on March 22, 2021, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which is available on the SEC&#8217;s website at </font><font style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:93.1pt;width:100%"><div style="text-align:right"><img alt="image_01.jpg" src="image_01.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Relations Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Brendan Payne</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stern Investor Relations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1-972-499-3350</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investor.relations&#64;instilbio.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.instilbio.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1-833-446-7845 Ext. 1009</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mediarelations&#64;instilbio.com</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_01.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 image_01.jpg
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MT W9%56'+KNRUDU\0T1$71F#(A$1$8F0:,(0(7%_63E>\FS&D-OST,>990?
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M%=*L&]G( $E$;<&@2$1$79*NBJFZV54&=62MW(>)_YF/OSY<@)_?MQ#GW[4
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M%#I57C>WFD8EZTD*@EN.PKJK+_C%>:$H4A1!4?1*4AVYYC$L!O4:1>(?]W;
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MB&*^S8%QW\7CNKN[J/86'!Y91=)D55%S@\6QK]_$BMN?ZHZQWTS!_N,GQ#5
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MIRB*O]Z][Q#B7AL';=VF,>VJ;E@TKFP:BW<G3$>^S1X@XXG:J*S=Y<*@CW[
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MG!PX>E)(_S>XIGF,GJZD:D11OD=(6!3JBWV\Z:$>Z#OL<Z0M78-C)T_#9G?
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MDAONZH#WOYR&H^E:7D^_N(V2@(*B:%(HBB; [T117^L!J(B@,U8=Q@-#TO#
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M=)1E&@E]2F?1^\L1QD3U_O+SJ[O,0>QG:Y"R\0C.9.<(T72J#K6<CNKR5%#
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MS,GJ])L1&XHBU'DE^Q7'3IW!U/B%:-O[/=QP;Q>$AEOU-!H!,K(8'JE&2F7
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MRO6(#>(2\-]WEF'2TOTXF9.KY6YT.8O7)E9R-54*%$6*(@)+%(-+K.OR%B5
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MOWM]YQ2T>&4!V@J9>'G29GR[8#<V[#N%,WE:Y[/FHW4_I,ADY.;C3$YAN=N
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MBH000@@AA!!"?* H$D(((8000@CQ@:)(""&$$$(((<2'_P>B7>=;$3W*"P
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
